IPSC Century Therapeutics, Inc.

Nasdaq centurytx.com


$ 0.58 $ -0.01 (-1.5 %)    

Friday, 31-Oct-2025 15:58:50 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 0.5831
$ 0.59
$ 0.57 x 1,000
$ 0.61 x 800
$ 0.58 - $ 0.60
$ 0.34 - $ 1.83
653,047
na
50.37M
$ 1.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-19-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 century-therapeutics-files-for-mixed-shelf-offering-of-up-to-200m

- SEC Filing

 chardan-capital-maintains-buy-on-century-therapeutics-lowers-price-target-to-6

Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target ...

 century-therapeutics-q1-eps-089-beats-016-estimate-sales-10916m-beat-4955m-estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-maintains-buy-on-century-therapeutics-lowers-price-target-to-2

HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price...

 guggenheim-reiterates-buy-on-century-therapeuticsto-buy

Guggenheim analyst Kelsey Goodwin reiterates Century Therapeutics (NASDAQ:IPSC) from Buy to Buy.

 chardan-capital-maintains-buy-on-century-therapeutics-lowers-price-target-to-7

Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target ...

 guggenheim-maintains-buy-on-century-therapeutics-lowers-price-target-to-5

Guggenheim analyst Kelsey Goodwin maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $...

 piper-sandler-maintains-overweight-on-century-therapeutics-lowers-price-target-to-2

Piper Sandler analyst Edward Tenthoff maintains Century Therapeutics (NASDAQ:IPSC) with a Overweight and lowers the price ta...

 century-therapeutics-announces-preclinical-pipeline-re-prioritization-to-focus-on-four-potentially-transformative-programs-to-advance-toward-clinic-led-by-cnty-308-in-b-cell-mediated-autoimmune-diseases-and-malignancies-new-concentrated-clinical-focus-for-cnty-101-based-on-unique-profile-with-transformational-potential-in-autoimmune-disease-data-anticipated-in-2025

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CN...

 century-therapeutics-receives-nasdaq-notice-for-bid-price-deficiency

- SEC Filing

 guggenheim-reiterates-buy-on-century-therapeuticsto-buy

Guggenheim analyst Michael Schmidt reiterates Century Therapeutics (NASDAQ:IPSC) from Buy to Buy.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION